Indivior Pharmaceuticals, Inc 6-K, filed Aug 6, 2024
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2024-08-06
For: 2024-08-06
View Original
Added on
April 10, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on August 6, 2024.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of August 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
No.
|
Description
of Exhibit
|
|
99.1
|
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: August 06, 2024
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
INDIVIOR PLC (THE 'COMPANY')
Completion of Share Repurchase Program
August 6, 2024
Indivior PLC announces that the share repurchase program announced
on November 17, 2023 to repurchase its ordinary shares of $0.50
each (the "Shares") for cancellation has now
completed.
In aggregate, Morgan Stanley & Co. International Plc, who
undertook the program on the Company's behalf, purchased 5,944,547
Shares for a total consideration of $99,985,139.07 at an
average price of £13.2821 per Share.
Following completion of the above program, the Company has now
commenced the share repurchase program announced on July 25, 2024
under which it will purchase Shares for up to a maximum
consideration of $100m during the period commencing on the
business day following the completion of the above program and
ending no later than January 31, 2025.
Contact:
Jason Thompson
Vice President, Investor Relations
1-804-402-7123
Indivior PLC's Legal Entity Identifier code is
213800V3NCQTY7IED471.